

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM602648

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Hayfin Services LLP, as Collateral Agent		09/16/2020	Limited Liability Partnership: ENGLAND AND WALES
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Eyevance Pharmaceuticals LLC		
<b>Street Address:</b>	777 Taylor Street, Suite 1050		
<b>City:</b>	Fort Worth		
<b>State/Country:</b>	TEXAS		
<b>Postal Code:</b>	76102		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 11</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	2855325	FRESHKOTE	
<b>Registration Number:</b>	3490217	NEXAGON	
<b>Registration Number:</b>	1960827	VEXOL	
<b>Serial Number:</b>	87399098	KLEERKOTE	
<b>Serial Number:</b>	87399116	CLEARKOTE	
<b>Serial Number:</b>	88303588	VISOVANQ	
<b>Serial Number:</b>	88303984	ECONOPRED	
<b>Serial Number:</b>	88304021	TOBRASONE	
<b>Serial Number:</b>	88359282	HYDRELLA	
<b>Registration Number:</b>	1182659	NATACYN	
<b>Serial Number:</b>	88304007	TOBRAFLEX	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	4152687522		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	415-261-6538		
<b>Email:</b>	kgalt@mofo.com		
<b>Correspondent Name:</b>	Jennifer Taylor, Morrison & Foerster LLP		
<b>Address Line 1:</b>	425 Market Street		

CH \$290.00 2855325

<b>Address Line 4:</b>	San Francisco, CALIFORNIA 94105
<b>ATTORNEY DOCKET NUMBER:</b>	62751.14
<b>NAME OF SUBMITTER:</b>	Muzamil Huq
<b>SIGNATURE:</b>	/Muzamil Huq/
<b>DATE SIGNED:</b>	10/13/2020
<b>Total Attachments: 4</b> source=Hayfin - Termination and Release Agreement - Trademarks#page1.tif source=Hayfin - Termination and Release Agreement - Trademarks#page2.tif source=Hayfin - Termination and Release Agreement - Trademarks#page3.tif source=Hayfin - Termination and Release Agreement - Trademarks#page4.tif	

## TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS

This TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS, dated as of September 16, 2020 (“Release”), is made by Hayfin Services LLP, in its capacity as collateral agent (“Collateral Agent”), in favor of Eyevance Pharmaceuticals LLC, a Delaware limited liability company (the “Grantor”).

WHEREAS, pursuant to that certain (i) Guarantee and Collateral Agreement, dated as of October 15, 2019 (as amended, restated, supplemented, modified or otherwise changed from time to time, the “Security Agreement”), by the Grantor, Eyevance Pharmaceuticals Holdings Inc., a Delaware corporation, in favor of the Collateral Agent, and (ii) Trademark Security Agreement, dated as of October 15, 2019, by the Grantor in favor of the Collateral Agent (as amended, restated, supplemented, modified or otherwise changed from time to time, the “Trademark Security Agreement”), the Grantor granted to the Collateral Agent a security interest in all of its Collateral, including those Pledged Trademarks and Pledged Trademark Licenses (each as defined in the Security Agreement) listed on Schedule 1 of the Trademark Security Agreement (the “Trademark Collateral”); and

WHEREAS, the Trademark Security Agreement was recorded at the United States Patent and Trademark Office (“USPTO”) on October 17, 2019 at reel 6774 frame 0107.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent agrees as follows:

SECTION 1. Defined Terms. All capitalized terms used herein but not otherwise defined herein have the meanings given to them in the Trademark Security Agreement.

SECTION 2. Termination and Release. The Collateral Agent hereby:

(a) terminates, cancels, discharges, and releases the security interest in and to all of the Trademark Collateral, including, but not limited to, the Trademark Collateral listed on Schedule A attached hereto, granted pursuant to the Security Agreement and the Trademark Security Agreement; and

(b) authorizes the recordation of this Release with the USPTO at the Grantor’s expense.

SECTION 3. Choice of Law. This Release shall be governed by and construed in accordance with New York law, without regard to principles of conflicts of laws that would result in the application of the law of any other jurisdiction.

[signature page follows]

IN WITNESS WHEREOF, the Collateral Agent has caused this Termination and Release of Security Interest in Trademarks to be duly executed as of the date first set forth above.

HAYFIN SERVICES LLP, as Collateral Agent

By: 

Name: \_\_\_\_\_

Title:

**Schedule A**  
**Trademark Registrations and Applications**

Owner	Country	Mark	Serial Number	Filing Date	Reg. Number	Reg. Date.
Eyevance Pharmaceuticals LLC	US	FreshKote	78/231,627	3/29/2003	2855325	6/15/2004
Eyevance Pharmaceuticals LLC	US	NEXAGON	78/602,587	4/5/2005	3490217	8/19/2008
Eyevance Pharmaceuticals LLC	US	VEXOL	74/479,305	1/13/1994	1960827	3/5/1996
Eyevance Pharmaceuticals LLC	US	KleerKote	87399098	4/5/2017		
Eyevance Pharmaceuticals LLC	US	ClearKote	87399116	4/5/2017		
Eyevance Pharmaceuticals LLC	US	VISOVANQ	88303588	2/15/2019		
Eyevance Pharmaceuticals LLC	US	ECONOPRED	88303984	2/15/2019		
Eyevance Pharmaceuticals LLC	US	TOBRASONE	88304021	2/15/2019		
Eyevance Pharmaceuticals LLC	US	TOBRAFLEX	88304007	2/15/2019		
Eyevance Pharmaceuticals LLC	US	HYDRELLA	88359282	3/27/2019		

Trademark	Country	Filing Type	Class	Current Status	Filing Status	Filing Number	Registration Date	Registration Number	Next Renewal Due	Legal Owner	Comment
NATAACYN & In Chinese	China	MF		S Renewal	30 Dec 1999	159448	07 Mar 2001	1530813	06 Mar 2021	Novartis AG	
NATAACYN	United States of America	MF		S Renewal	17 Dec 1999	73243188	22 Dec 1999	1182058	22 Dec 2021	Novartis AG	
NATAACYN	European Union	EM		S Renewal	31 Oct 2009	003021759	04 Feb 2009	003021298	31 Oct 2029	Novartis AG	
NATAACYN	Guatemala	MF		S Renewal	23 Oct 1998	1489-1363	16 Nov 1998	10869	15 Nov 2019	Novartis AG	
NATAACYN	Australia	MF		S Renewal	02 Jul 2007	1184888	02 Jul 2007	1184888	02 Jul 2027	Novartis AG	
NATAACYN	Thailand	MF		S Renewal	04 Apr 2007	857727	04 Apr 2007	80274413	01 Apr 2027	Novartis AG	
NATAACYN	Malaysia	MF		S Renewal	20 Apr 2007	2637/071134	20 Apr 2007	3017-071134	20 Apr 2027	Novartis AG	
NATAACYN	Argentina	MF		S Renewal	20 Feb 2009	24962567	16 Feb 2009	19851137	14 Jul 2029	Novartis AG	
NATAACYN	Colombia	MF		S Renewal	08 Nov 2000	85197	22 Nov 2003	262295	22 Nov 2023	Novartis AG	
NATAACYN	Mexico	MF		S Registration	04 Oct 2017	86079/2017	05 Feb 2018	13419/2018	04 Oct 2027	Novartis AG	

NATACYN	vietnam	NF	5 Application of Application	02 May 2008	25926 4-2008-09258					Novartis AG	*Trademark application NATACYN No. 4-2008-09258 filed on May 02, 2008 is still pending based on the filed appeal of Novartis AG against the decision from the registrar based on NATACINA vs NATACYN
NATACYN	Uruguay	NF	5 Filed/pending	03 oct 2019	508652					Novartis AG	

### Trademark Licenses

Country	Mark	Serial Number	Filing Date	Reg. Number	Reg. Date.
US	FLAREX	73/617,344	8/29/1986	1437695	4/28/1987
US	ZERVIAE	88/063,436	8/2/2018		

#### TO BE LICENSED

Product 1 / Trade Name: TOBRADEX SY / ALCON NATACYN

Trademark	Country	Filing Type	Class	Current Status	Filing Date	Filing Number	Registration State	Registration Number	Next Renewal Due	Legal Owner	Comment
TOBRADEX	US	NF	5	Renewal	18 Apr 1994	74301978	06 Jun 1995	1697276	06 Jun 2025	Novartis AG	
ALCON NATACYN	Costa Rica	NF	5	Renewal	09/ Jun 2000	42947	10/ Jun 2003	242600	10/ Jun 2021	Novartis AG	
ALCON NATACYN	Mexico	NF	5	Registration	09/ Sep 2011	1215771	23/ Aug 2012	1305812	29/ Sep 2022	Novartis AG	
ALCON NATACYN	Uruguay	NF	5	Registration	13/ Apr 2007	599585	10/ Apr 2008	379585	10/ Apr 2019	Novartis AG	Request to maintain 22 Dec 2017
ALCON NATACYN	Venezuela	NF	5	Registration	21/ Jun 2007	14364-2007	23/ Jun 2008	0280140	23 June 2018	Novartis AG	Request to maintain 28 Feb 2019
ALCON NATACYN	Vietnam	NF	5	Filed/pending	25 dec 2017	4-2017-43234				Novartis AG	

#### TO BE ASSIGNED/TRANSFERRED

Product 2 / Trade Name: NATACYN